



## **2021 Canadian Sleep Society (CSS) Annual Meeting (Virtual): Eisai Inc. Sponsored Oral Presentations and Posters**

Please see the Eisai Inc. sponsored oral presentations and posters presented at the 2021 Canadian Sleep Society (CSS) Annual Meeting below and refer to the Congress Links section available on our Medical Information website which may include additional information.

### **LEMBOREXANT**

1. Landry I, Hall N, Aluri J, et al. Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared with Suvorexant and Zolpidem in Recreational Sedative Users. Poster presented at: Canadian Sleep Society (CSS) Annual Meeting; October 28-Oct 30, 2021; Virtual.
2. McElroy H, O'Leary B, Adena M, et al. Insomnia Treatments and On-the-Road Driving Performance: A Systematic Literature Review. Poster presented at: Canadian Sleep Society (CSS) Annual Meeting; October 28-Oct 30, 2021; Virtual.
3. Moline M, Inoue Y, Pinner K, et al. Long-Term Efficacy and Safety of Lemborexant Versus Placebo for the Treatment of Insomnia in Elderly Adults. Oral Presentation presented at: Canadian Sleep Society (CSS) Annual Meeting; October 28-Oct 30, 2021; Virtual.
4. Moline M, Cheng JY. Safety and Efficacy of Lemborexant Over the Long-Term in Subjects with Irregular Sleep-Wake Rhythm Disorder and Alzheimer's Disease Dementia. Oral Presentation presented at: Canadian Sleep Society (CSS) Annual Meeting; October 28-Oct 30, 2021; Virtual.
5. Pokrzywinski R, Abel C, Lenderking WR, et al. Signs and Symptoms of Irregular Sleep-Wake Rhythm Disorder (ISWRD) Reported Directly from Patients with Dementia and Their Caregivers. Oral Presentation presented at: Canadian Sleep Society (CSS) Annual Meeting; October 28-Oct 30, 2021; Virtual.
6. Rosenberg R, Kumar D, Perdomo C, et al. Next-Dose Transition from Zolpidem to Lemborexant: Results From a 14-Week Multicenter Open-Label Pilot Study. Poster presented at: Canadian Sleep Society (CSS) Annual Meeting; October 28-Oct 30, 2021; Virtual.
7. Yardley J, Inoue Y, Pinner K, et al. Effectiveness and Safety of the Dual Orexin Receptor Antagonist Lemborexant in Subjects Previously Treated with Placebo for 6 Months. Oral Presentation presented at: Canadian Sleep Society (CSS) Annual Meeting; October 28-Oct 30, 2021; Virtual.

**IMPORTANT INFORMATION - PLEASE READ:**

If you would like a full copy of the poster(s) listed above, please submit your request via [www.eisaimedicalinformation.com/neurology/medicalinquiry](http://www.eisaimedicalinformation.com/neurology/medicalinquiry) or the Submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Presentation or Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at [esi\\_medinfo@eisai.com](mailto:esi_medinfo@eisai.com) or call 1-888-274-2378.